Several other molecular and clinical parameters that may indicate a better response to a PD-L1 blockade strategy include total mutation burden, histology (squamous epithelial differentiation status), frequencies of TILs, PD-L2 expression, ratio of T-reg and CD8+-T-cell frequencies, lymphoid aggregates, and degree of tumour necrosis. Here, CD8A is linked to neoplasm.